BIO-TECHNE Corp
TECH- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000842023
No open-market purchases or sales by BIO-TECHNE Corp insiders were filed in the last 90 days; 597 institutions reported holding it in 13F filings for Q2 2026, worth $12.3B in total; 3 superinvestors hold it, including Maverick Capital and Weitz Investment Management.
Q2 2026 vs. Q1 2026
How the institutions holding BIO-TECHNE Corp changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Of which not filed for Q2 2026 | Q2 2026 | Change |
|---|---|---|---|---|
| Holders | 585 | 6 | 597 | +18 |
| Shares | 177.4M | 110.0K | 175.3M | −2.01M (−1.1%) |
| Value | $9.29B | $5.75M | $12.3B | +$3.06B (+33.0%) |
6 institutions that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (130)
Institutions that held BIO-TECHNE Corp at the end of Q2 2026 but not at the end of Q1 2026.
Showing the largest 100 of 130 by value.
Sold out (112)
Institutions that held BIO-TECHNE Corp at the end of Q1 2026 and filed for Q2 2026 without it.
Showing the largest 100 of 112 by value.
Not filed for Q2 2026 yet (6)
Institutions that held BIO-TECHNE Corp at the end of Q1 2026 and haven't filed a 13F for Q2 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Janus Henderson Group PLC | 68,019 | $3.56M |
| Signature Wealth Management Group | 15,740 | $822.6K |
| CWM, LLC | 12,591 | $658.0K |
| Gibbs Wealth Management | 8,131 | $424.9K |
| Skopos Labs, Inc. | 5,406 | $282.5K |
| Red Tortoise LLC | 88 | $4.60K |